Counselors in Fort Hall, ID Accepting Medicare
4 Counselors found. Showing 1 - 4
 Sandra Ortiz, ICADC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 115 Pima Drive, Fort Hall, ID 83203 Phone: 208-238-2400 Fax: 208-238-5462 |
 Gary Dale Conder, ICADC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 115 Pima Drive, Fort Hall, ID 83203 Phone: 208-238-2400 Fax: 208-238-5462 |
Ms. Scotti L Brownley, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: Mission Road Bldg 248, Fort Hall Indian Agency, Fort Hall, ID 83203 Phone: 208-237-5631 Fax: 208-237-5796 |
Nava Reneda, CADC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: East Agency Rd, Fort Hall, ID 83203 Phone: 208-238-2400 Fax: 208-238-5462 |
News Archive
Perineal massage helps childbirth
Low-tech, at-home preparation in the last month before childbirth could help pregnant mothers avoid one of the more common surgeries performed on women in the United States, a new review suggests.
Lead exposure risks come from both ends of firearms, IUPUI study finds
Risks from firearms actually come from both ends of the barrel, according to an Indiana University-Purdue University Indianapolis study.
Link between sleep disorders, diet, exercise and technology use in adolescents
According to a research abstract that will be presented on Tuesday, June 9, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, adolescent obesity is associated with having less sleep. Reduction in sleep could be related to a higher caffeine intake, more hours of technology use and increased symptoms of sleep disorders (such as snoring).
Suberoylanilide hydroxamic acid holds promise against familial frontotemporal dementia
A drug already approved for people with cancer shows early potential as a therapy for a common form of dementia, UT Southwestern Medical Center researchers report.
Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer
Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.
› Verified 9 days ago